EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes

Rudolf Janzen

Neurology International Open · 01.04.2018 · 2 (02) · E118-E123

DOI: 10.1055/s-0044-100184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurology International Open, erschienen am 01.04.2018. Verfasst von Rudolf Janzen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The off-label use of licensed drugs is widespread, and the risk of adverse events is elevated, especially if the scientific evidence is low. The treatment of rare diseases (

Zitieren

APA

Janzen, R. (2018). Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes. Neurology International Open, 2(02), E118-E123. https://doi.org/10.1055/s-0044-100184

Vancouver

Janzen R. Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes. Neurology International Open. 2018;2(02):E118-E123. doi:10.1055/s-0044-100184

BibTeX
@article{Janzen2018,
  author = {Janzen, Rudolf},
  title = {Off-Label Use in Rare Diseases: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes},
  journal = {Neurology International Open},
  year = {2018},
  volume = {2},
  number = {02},
  pages = {E118--E123},
  doi = {10.1055/s-0044-100184}
}
Kostenlos starten →